Advertisement

Rheumaderm pp 187-191 | Cite as

Dermatomyositis and Drugs

  • Assen L. Dourmishev
  • L. A. Dourmishev
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 455)

Abstract

Dermatomyositis (DM) is an idiopathic inflammatory disorder consisting of skin and skeletal muscle involvement. Patients with skeletal muscle involvement have polymyositis (PM), and those unresponsive to therapy and with characteristic findings on muscle biopsy have inclusion body myositis. Patients without muscle damage and typical skin lesions have amyopathic dermatomyositis. Disease in children (juvenile dermatomyositis) is not associated with malignancy as it may be in adults (paraneoplastic dermatomyositis). Overlap syndrome (OS) is mixed connective tissue disease combining some features of DM, SS and LES. Scleromyositis is overlap syndrome associated with anti-PM-Scl antibodies. Patients with PM, DM or OS with “interstitial lung disease” and anti-synthetase antibodies have an “anti-synthetase syndrome”. Various drugs, including d-penicillamine, NSAIDs, anti-infectious agents, as well as lipid lowering drugs, the HMG-CoA reductase inhibitors may cause myopathy and skin lesions (drug induced dermatomyositis). “Dermatomyositis” occurring as adverse reactions of drugs are rare, irregular and impossible to predict in individual patients. They are very interesting in that they may be keys for explaining the pathogenic mechanisms of the disease.

Keywords

Interstitial Lung Disease Inclusion Body Myositis Zidovudine Therapy Juvenile Dermatomyositis Systemic Scleroderma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bohan A, Peter, J.B. Polymyositis and dermatomyositis. N. Engl. J. Med. 292, 345–7 (1975).Google Scholar
  2. 2.
    Euwer R., Sontheimer, R. Amyopathic dermatomyositis: a review. J. Invest. Dermatol. 100, 124S–128S (1993).PubMedCrossRefGoogle Scholar
  3. 3.
    Dalakas M.C. Polymyositis, dermatomyositis and inclusion-body myositis. N. Engl. J. Med. 325: 1487–98 (1991).PubMedCrossRefGoogle Scholar
  4. 4.
    Ponge A., Mussini J.M., Ponge T. et al. Dermatopolymyosiyis paraneoplasiques. Rev. Med. Int. 8: 251–256 (1987).CrossRefGoogle Scholar
  5. 5.
    Jablonska S., Blazczyk M., Chorzelski T., Jarzabek-Chorzelska M. Connective tissue disease (CTD) overlap syndromas. Int. Meet. Clin. Dermatol., Athens, 28–31 March. Absreact, 64–65 (1996).Google Scholar
  6. 6.
    Targoff I.N. Humoral Immunity in Polymyositis/Dermatomyositis. J. Invest. Dermatol. 100: 116S–123S (1993).PubMedCrossRefGoogle Scholar
  7. 7.
    Mackie B. Dermatomyositis induced by drugs. Austr. J. Dermatol. 8: 249–251 (1966).Google Scholar
  8. 8.
    Fayolle J., Vallon C, Claudy A et al. Dermatomyositis induite par l’isoniazide. Lyon Med. 223: 135–138 (1975).Google Scholar
  9. 9.
    Fernandes I., Swinson D.R., Hamilton E. Dermatomyositis complicating penicillamine treatment. Ann. Rheum. Dis. 36: 94–5(1977).PubMedCrossRefGoogle Scholar
  10. 10.
    Cotterill J.A., Shapiro H. Dermatomyositis after immunisation. Lancet ii: 1158–1159 (1978).CrossRefGoogle Scholar
  11. 11.
    Simpson N.B., Golding J.R. Dermatomyositis induced by penicillamine. Acta Derm. Venereol., (Stockh) 59: 543–4(1979).PubMedGoogle Scholar
  12. 12.
    Mackie B.S., Mackie L.E. Lupus erythematosus; dermatomyositis induced by sulphacetamide eye drops. Clin. Exp. Dermatol. 4: 111–113 (1979).PubMedCrossRefGoogle Scholar
  13. 13.
    Lund H.I., Nielsen M. Penicillamine-induced dermatomyositis. Scand. J. Rheumatol., 12: 350–2 (1983).PubMedCrossRefGoogle Scholar
  14. 14.
    Car J., Lorette G., Jacob C. Dermatomyosite induite par la d-penicillamine. Sem. Hop. 63: 399–403 (1987).Google Scholar
  15. 15.
    Kolsi R., Bahloul Z., Hachicha J., et al. Dermatomyosite induite par la d-penicillamine au cours d’une polyarthrite rheumatoide. A propose d’un cas avec revue de la literature. Rev. Rheum. Mal. Osteo. Articulaires. 59: 341–44(1992).Google Scholar
  16. 16.
    Jani RM., Gray J.P., Lanham J. Influenza vaccine and dermatomyositis. Vaccine 12/15: 1484 (1994).PubMedCrossRefGoogle Scholar
  17. 17.
    Chapurlat R., Tebib J.G., Noel E., et al. Dermatomyosite induite par la d-penicillamine au cours d’une polyarthrite rheumatoide. Rhumatologie. 47: 203–207 (1995).Google Scholar
  18. 18.
    Umeda Y., Mizutani H., Shimizu M. A case of dermatomyositis with aspiration pneumonia induced by contrast media. Nishinihon J. Dermatol. 57: 454–57 (1995).CrossRefGoogle Scholar
  19. 19.
    Harkcom T.H., Conn D.L. Holley K.E. D-Penicillamine and lupus erythematosus-like syndrome. Ann. Intern. Med. 89: 1012 (1978).PubMedGoogle Scholar
  20. 20.
    Grob J.J., Collet A.M., Bonerandi J.J. Dermatomyositis-like syndrome induced by nesteroid anti-inflammatory agents. 178: 258–262(1989).Google Scholar
  21. 21.
    Richard M., Trucheter F., Friedel J. et at. Skin lesions simulating chronic dermatomyositis during longterm hydroxyurea therapy. J. Am. Acad. Dermatol. 21: 797–99 (1989).PubMedCrossRefGoogle Scholar
  22. 22.
    K. Zurcher, A.Kreps Dermatomyositis-Like Syndrome (*Polymyositis). In: Cutaneous Drug Reactions, Basel, Karger 360 (1992).Google Scholar
  23. 23.
    Hanissai A.S., Martinez A.J., Labbour J.T. et al. Vasculitis and myositis secondary to rubeola vaccination. Arch. Neurol., 1973, 28: 202–204.CrossRefGoogle Scholar
  24. 24.
    Nishikai M., Funatsu Y., Homa M: Monoclonal gammapathy, penicilamine-induced polymyositis and systemic sclerosis. Arch. Dermatol., 1974, 110: 253–255.PubMedCrossRefGoogle Scholar
  25. 25.
    Cucher B.G., Goldman A.I. D-Penicillamine induced polymyositis in rheumatoid arthritis. Ann. Intern. Med. 85: 615–6(1976).PubMedGoogle Scholar
  26. 26.
    Tomlinson I.W., Rosenthal F.D. Proximal myopathy after perhexileme maleate treatment. Br. Med. J. i, 1319–1320 (1977).CrossRefGoogle Scholar
  27. 27.
    Schlumpf U., Bussman H.U., Jerusalem F. Myositis bei chronischer Polyarthritis unter d-Penicillamin, medicmentos induziert? Schweiz. Med. Wochenschr. 111: 29–35 (1981).PubMedGoogle Scholar
  28. 28.
    Doyle DR., McCurley T.I., Sergent J.S. Fatal polymyositis in d-penicillamine-treated rheumatoid arthritis. Ann. Intern. Med. 98: 327–30(1983).PubMedGoogle Scholar
  29. 29.
    Paradisi M., Parisi I., Valente G. et al. Le polimiositi iatrogene. ImpegoOsp. Sez. Sci. 10/4: 39–40 (1989).Google Scholar
  30. 30.
    Bessen L.J., Green J.B., Louie E. et al. Severe polymyositis-like syndrome associated with zidovudine therapy of AIDS and ARC. N. Engl. J. Med. 318: 708 (1988).PubMedGoogle Scholar
  31. 31.
    Fusella J., Strosberg J.M. Polymyositis exacerbed by gemfibrocil. J. Rheumatol. 17: 572 (1990).PubMedGoogle Scholar
  32. 32.
    Sauvage F., Piette J.C., Herson S. et al. Fenofibrate-induced polymyositis. Rev. Med. Interne. 12: 52–54 (1991).CrossRefGoogle Scholar
  33. 33.
    Hodak E., Gadoth N., David M. et al. Muscule damage induced by isotretionin. Br. Med. J. 293: 425–6 (1986).CrossRefGoogle Scholar
  34. 34.
    Hodak E., David M., Gadoth N., et al. Etretinate induced muscule damage. Br. J. Dermatol. 116: 623–6 (1987).PubMedCrossRefGoogle Scholar
  35. 35.
    Ross N.S. et al. Ibuprofen induced myopathy. JAMA 257: 1258 (1987).Google Scholar
  36. 36.
    Foon K.A. et al. Myalgia from interferon alpha. N. Engl. J. Med. 19, 1259 (1984).Google Scholar
  37. 37.
    Cronkright P.J. et al. Isoniazid and myopathy. Ann. Intern. Med. 110: 945 (1989).PubMedGoogle Scholar
  38. 38.
    Gaty B.Z. et al. Ketoconazol and myopathy. Am. J. Dis. Child. 145: 970 (1991).Google Scholar
  39. 39.
    Kogan A.D. et al. Lovastatin and myopathy. Postgr. Med. 66: 294. (1990).CrossRefGoogle Scholar
  40. 40.
    Vaher V.M.G. et al. Lovastatin and myopathy. Lancet 2, 1098 (1989).Google Scholar
  41. 41.
    Engel J.N. et al. Dipheylhydantoin and myopathia. Am. J. Med. 81: 928 (1986).PubMedCrossRefGoogle Scholar
  42. 42.
    Harney J. et al. Dipheylhydantoin and myopathia. Neurology 33: 790 (1983).PubMedCrossRefGoogle Scholar
  43. 43.
    Jacyk WK. Elevated CPK associated with the use of etretinate. J. Am. Acad. Dermatol. 15: 710 (1984).CrossRefGoogle Scholar
  44. 44.
    McBurney EL, Rosen DA. Elevated creatin phosphokinase with isotretionin. J. Am. Acad. Dermatol. 10: 528–9(1983).CrossRefGoogle Scholar
  45. 45.
    Chen D., Rodsky HE. Elevated CPK and isotretionin. J. Am. Acad. Dermatol. 12: 582–83 (1985).CrossRefGoogle Scholar
  46. 46.
    Shelley W.B. Birch pollen and aspirin psoriasis. JAMA 189: 986–988 (1964).Google Scholar
  47. 47.
    Shelley W.B. Futher expereriences with an indirect basophil test. Arch. Dermatol. 91: 165–170 (1965).CrossRefGoogle Scholar
  48. 48.
    Espana A., Serna M.J. Etiopatogenia de la dermatomyositis. Monogr. Dermatol. 6/3: 166–172 (1993).Google Scholar
  49. 49.
    Parker C.W. Drug allergy. N. Engl. J. Med. 292; 511; 732; 957 (1975).PubMedCrossRefGoogle Scholar
  50. 50.
    Bessen L.J., Green J.B., Louie E. et al. Severe polymyositis-like syndrome associated with zidovudine therapy of AIDS and ARC. N. Engl. J. Med. 318: 708. (1988)PubMedGoogle Scholar
  51. 51.
    Dalakas M.C., Illa I., Pezeshkpour G.H., et al. Mitochondrial myopathy caused by long-term zidovudine therapy. N. Engl. J. Med. 322: 1098–1105 (1990).PubMedCrossRefGoogle Scholar
  52. 52.
    Arnaudo E., Dalakas M.C., Shanske S., et al. Depletion of muscle mitochondrial DNA in AIDS patients with zudovudine-induced myopathy. Lancet 337: 508–510 (1991).PubMedCrossRefGoogle Scholar
  53. 53.
    Fusella J., Strosberg J.M. Polymyositis exacerbed by gemfibrocil. J. Rheumatol., 17: 572 (1990).PubMedGoogle Scholar
  54. 54.
    Sauvage F., Piette J.C., Herson S. et al. Fenofibrate-induced polymyositis. Rev. Med.Interne 12: 52–54 (1991).CrossRefGoogle Scholar
  55. 55.
    Schalke B.B., Schmidt B., Toyka K. et al. Pravastatin and dermaromyositis. N. Engl. J. Med. 327: 649 (1992).PubMedGoogle Scholar
  56. 56.
    Khattak F.H., Morris I.M., Branford W.A. Simvastatin-associated dermatomyositis. Br. J. Rheumatol. 33: 199 (1994).PubMedCrossRefGoogle Scholar
  57. 57.
    Norman D.J., Iillingworth D.R., Munson J. et al. Myositis and acute renal failure in a heart transplantant recipient receiving lovastatin. N. Engl. J. Med. 318: 46–47 (1988).PubMedCrossRefGoogle Scholar
  58. 58.
    Bilheimer D.W. Myopathy from simvastatin. Cardiology, 77, Suppl, 4: 58 (1990).PubMedCrossRefGoogle Scholar
  59. 59.
    Deslypere J.P. et al. Myopathy from simvastatin. Ann. Intern. Med, 114: 342 (1991).PubMedGoogle Scholar
  60. 60.
    al-Jubouri M.A. Briston P.G., Sinclair D. et al. Myxoedema revealed by simvastatin indiced myopathy. BMJ., 308: 588 (1994)PubMedCrossRefGoogle Scholar
  61. 61.
    Monk B.E., Pembroke A.C. Dermatomyositis following radiotherapy. Br. J. Dermatol., (suppl. 24): 103 (1983).CrossRefGoogle Scholar
  62. 62.
    Harris A.L., Smith I.E., Snaith M. Tamoxifen-induced tumor regression associated with dermatomyositis. Br. Med. 1, 284: 1674–5 (1982).CrossRefGoogle Scholar
  63. 63.
    Litt J.Z., Pawlak W.A. Drug Eruption Reference Manual, Parthen. Publ. Group, 344–6 (1997).Google Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • Assen L. Dourmishev
    • 1
  • L. A. Dourmishev
    • 1
  1. 1.Department of DermatologyUniversity of MedicineSofiaBulgaria

Personalised recommendations